Last reviewed · How we verify
ISIS 14803, peginterferon alfa, ribavirin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ISIS 14803, peginterferon alfa, ribavirin (ISIS 14803, peginterferon alfa, ribavirin) — Ionis Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ISIS 14803, peginterferon alfa, ribavirin TARGET | ISIS 14803, peginterferon alfa, ribavirin | Ionis Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ISIS 14803, peginterferon alfa, ribavirin CI watch — RSS
- ISIS 14803, peginterferon alfa, ribavirin CI watch — Atom
- ISIS 14803, peginterferon alfa, ribavirin CI watch — JSON
- ISIS 14803, peginterferon alfa, ribavirin alone — RSS
Cite this brief
Drug Landscape (2026). ISIS 14803, peginterferon alfa, ribavirin — Competitive Intelligence Brief. https://druglandscape.com/ci/isis-14803-peginterferon-alfa-ribavirin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab